フェイジン＆チェリー小児感染症テキスト（第９版・全２巻）
Feigin and Cherry’s Textbook of Pediatric Infectious Diseases 9th Edition
Edited by By James Cherry, Gail J. Demmler-Harrison, Sheldon L. Kaplan, William J. Steinbach, Peter J. Hotez, and John V. Williams
2024/11 9th ed. 2 vols. 3,064 p. 1,060 figs. ISBN 978-0-323-82763-8 (Elsevier) -US-
set USD 409.99
Web販売価格 ￥68,120（税込） / 標準価格 ￥91,098（税込）
*2025年1月27日時点の価格です。実際の価格は、為替レートや出版社の都合により変動いたしますので、最新の価格は以下オンラインストアリンクをご参照ください。
*Web販売価格は、紀伊國屋書店BookWeb Proでご注文され、付帯作業を伴わない納品を行い、弊社標準書式による請求書を発行し遅滞なくお支払いただく場合、あるいは、クレジットカードでお支払いいただく場合に適用される販売価格です。
概要
定評あるフェイジン＆チェリーの小児感染症テキスト改訂第9版。疫学、公衆衛生、予防医学から臨床兆候、診断、治療まで幅広く最新情報を網羅しています。微生物ごとに感染症を解説するだけでなく器官ごとの解説も掲載しており、感染症を引き起こす微生物と関連のある臨床所見に焦点を当てています。
今回の版では、Q熱、抗菌薬耐性、抗菌薬、ヒトコロナウイルス、ポックスウイルス、 易感染性宿主における感染症に関する情報を拡充し、複数の章でCOVID-19に関する新規コンテンツを収録しています。
*前版: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 8th ed. (2018) ISBN 9780323376921
価格照会・ご購入
※本件についてのお問い合わせ、お見積りについては最寄りの紀伊國屋書店営業所もしくはこちらまでお願いいたします。
収録内容明細
VOLUME ONE
Part I. Host-Parasite Relationships and the Pathogenesis of Infectious Diseases
1. Molecular Determinants of Microbial Pathogenesis
COLONIZATION
TISSUE TROPISM
BIOFILMS
CELL ENTRY AND INTRACELLULAR LIFE
DAMAGE TO THE HOST
EVASION OF IMMUNITY
CONCLUSION
2. Normal and Impaired Immunologic Responses to Infection
HOST-PATHOGEN INTERACTIONS
FEATURES OF NORMAL IMMUNE FUNCTION
CLINICAL CONDITIONS ASSOCIATED WITH DEFICIENT HOST RESPONSES TO INFECTION
EVALUATION FOR IMMUNODEFICIENCY IN THE CHILD WITH RECURRENT OR SEVERE INFECTIONS
3. The Host Response to Infections: The “-omics” Revolution
INTRODUCTION
GENOMICS
EPIGENETICS
TRANSCRIPTOMICS
PROTEOMICS
METABOLOMICS
FUTURE PERSPECTIVES
4. Fever: Pathogenesis and Treatment
NORMAL BODY TEMPERATURE
THERMOREGULATION
PATHOGENESIS OF FEVER
EFFECTS OF FEVER
CLINICAL THERMOMETRY
TREATMENT
SUMMARY
5. The Human Microbiome
INTRODUCTION
THE HUMAN MICROBIOME: DEVELOPMENT IN EARLY LIFE THROUGH CHILDHOOD
ENVIRONMENTAL FACTORS AFFECTING THE PEDIATRIC MICROBIOME: DIET AND MEDICATIONS
THE HUMAN MICROBIOME: PIVOTAL ROLE OF METABOLITES
MICROBIOME AT DIFFERENT BODY SITES
SUMMARY
6. Epidemiology and Biostatistics of Infectious Diseases
EPIDEMIOLOGIC STUDIES
CAUSES OF DISEASE
BIOSTATISTICS
DIAGNOSTIC TESTS
ASSESSMENT OF THE PROTECTIVE EFFICACY OF A VACCINE (OR OF ANY INTERVENTION)
QUALITY IMPROVEMENT
Infection of Specific Organ Systems
Section 1. Upper Respiratory Tract Infections
7. The Common Cold
HISTORY
ETIOLOGIC AGENTS
EPIDEMIOLOGY
PATHOPHYSIOLOGY
CLINICAL PRESENTATION
DIFFERENTIAL DIAGNOSIS
SPECIFIC DIAGNOSIS
TREATMENT
PROGNOSIS
PREVENTION
8. Infections of the Oral Cavity
MICROBIOLOGIC CONSIDERATIONS IN DENTAL INFECTIONS
ANATOMIC CONSIDERATIONS
TREATMENT OF ODONTOGENIC INFECTIONS
COMPLICATIONS OF ODONTOGENIC INFECTIONS
OSTEOMYELITIS OF THE JAWS IN CHILDREN
ORAL MANIFESTATIONS OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN CHILDREN
ORAL CARE OF CHILDREN WITH CANCER
HERPES SIMPLEX VIRUS INFECTIONS
ORAL MANIFESTATIONS OF SARS-COV-2
INTRAORAL AND PERIORAL PIERCINGS
9. Pharyngitis (Pharyngitis, Tonsillitis, Tonsillopharyngitis, and Nasopharyngitis)
HISTORY
NASOPHARYNGITIS
PHARYNGITIS, TONSILLITIS, AND TONSILLOPHARYNGITIS
PERIODIC FEVER, APHTHOUS STOMATITIS, PHARYNGITIS, AND ADENITIS
10. Uvulitis
ETIOLOGY
EPIDEMIOLOGY
PATHOGENESIS
CLINICAL MANIFESTATIONS
DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
TREATMENT
11. Peritonsillar, Retropharyngeal, and Parapharyngeal Abscesses
EPIDEMIOLOGY OF HEAD AND NECK SPACE INFECTIONS IN CHILDREN
PERITONSILLAR ABSCESS (QUINSY)
RETROPHARYNGEAL ABSCESS (POSTERIOR VISCERAL SPACE, RETROVISCERAL SPACE, AND RETROESOPHAGEAL SPACE ABSCESSES)
PARAPHARYNGEAL ABSCESS (PTERYGOMAXILLARY, PHARYNGOMAXILLARY, LATERAL, AND PHARYNGEAL SPACE ABSCESSES)
MICROBIOLOGY OF DEEP NECK ABSCESSES
12. Cervical Lymphadenitis
EPIDEMIOLOGY
PATHOPHYSIOLOGY
CLINICAL PRESENTATION
DIFFERENTIAL DIAGNOSIS
SPECIFIC DIAGNOSIS
TREATMENT
PROGNOSIS
PREVENTION
13. Parotitis
PATHOPHYSIOLOGY
ETIOLOGY
CLINICAL PRESENTATION AND DIAGNOSIS
HUMAN IMMUNODEFICIENCY VIRUS AND PAROTID ENLARGEMENT
DIFFERENTIAL DIAGNOSIS
TREATMENT
COMPLICATIONS
PREVENTION
14. Rhinosinusitis
HISTORY
ANATOMY
PATHOPHYSIOLOGY
ETIOLOGY
EPIDEMIOLOGY
CLINICAL PRESENTATION
COMPLICATIONS
DIFFERENTIAL DIAGNOSIS
SPECIFIC DIAGNOSIS
TREATMENT
PROGNOSIS
PREVENTION
15. Otitis Externa
EPIDEMIOLOGY
NORMAL ANATOMY
PROTECTIVE MECHANISMS OF THE EXTERNAL EAR
NORMAL BACTERIAL FLORA
ACUTE OTITIS EXTERNA
CHRONIC OTITIS EXTERNA
OTOMYCOSIS
NECROTIZING OTITIS EXTERNA
DIFFERENTIAL DIAGNOSIS
PREVENTION
CONCLUSION
16. Otitis Media
EPIDEMIOLOGY OF ACUTE OTITIS MEDIA
PATHOGENESIS
DIAGNOSIS
EXAMINATION OF THE EAR
MANAGEMENT OF ACUTE OTITIS MEDIA
Treatment in the Penicillin-Allergic Child
OTITIS MEDIA WITH EFFUSION
RECURRENT ACUTE OTITIS MEDIA
Immunology
PREVENTION
Surgical Options
COMPLICATIONS AND SEQUELAE
ACKNOWLEDGMENTS
17. Mastoiditis
HISTORY
ANATOMY AND PATHOPHYSIOLOGY
MICROBIOLOGY
CLINICAL PRESENTATION
COMPLICATIONS
DIFFERENTIAL DIAGNOSIS
SPECIFIC DIAGNOSIS
TREATMENT
PROGNOSIS
PREVENTION
18. Croup (Laryngitis, Laryngotracheitis, Spasmodic Croup, Laryngotracheobronchitis, Bacterial Tracheitis, and Laryngotracheobronchopneumonitis) and Epiglottitis (Supraglottitis)
HISTORICAL ASPECTS
TERMINOLOGY
ETIOLOGY OF CROUP SYNDROMES
ETIOLOGY OF SUPRAGLOTTITIS
EPIDEMIOLOGY OF CROUP
EPIDEMIOLOGY OF SUPRAGLOTTITIS
PATHOLOGY AND PATHOGENESIS OF CROUP
ANATOMY AND PATHOPHYSIOLOGY OF SUPRAGLOTTITIS
CLINICAL PRESENTATION
DIFFERENTIAL DIAGNOSIS
SPECIFIC DIAGNOSIS IN CROUP SYNDROMES
SPECIFIC DIAGNOSIS IN SUPRAGLOTTITIS
TREATMENT OF CROUP
TREATMENT OF SUPRAGLOTTITIS
PROGNOSIS
PREVENTION OF CROUP
Section 2. Lower Respiratory Tract Infections
19. Acute Bronchitis
ETIOLOGY
EPIDEMIOLOGY
PATHOPHYSIOLOGY AND PATHOLOGY
CLINICAL PRESENTATION
DIFFERENTIAL DIAGNOSIS AND SPECIFIC DIAGNOSIS
TREATMENT
PROGNOSIS
PREVENTION
20. Chronic Bronchitis
DIFFERENTIAL DIAGNOSIS
EPIDEMIOLOGY AND ETIOLOGY
TREATMENT
21. Bronchiolitis and Infectious Asthma
DEFINITIONS
HISTORY
ETIOLOGIC AGENTS
EPIDEMIOLOGY
CLINICAL PRESENTATION
PATHOPHYSIOLOGY
DIFFERENTIAL DIAGNOSIS
DIAGNOSIS
TREATMENT
PREVENTION
COMPLICATIONS AND PROGNOSIS
22. Pediatric Community-Acquired Pneumonia
ETIOLOGY
EPIDEMIOLOGY
PATHOGENESIS
CLINICAL MANIFESTATIONS
DIAGNOSIS
MANAGEMENT
PREVENTION
23. Empyema and Lung Abscess
EMPYEMA
LUNG ABSCESS
24. Children’s Interstitial Lung Disease and Hypersensitivity Pneumonitis
CLASSIFICATION
CLINICAL PRESENTATION
DIAGNOSTIC EVALUATION
TREATMENT
OUTCOME
HYPERSENSITIVITY PNEUMONITIS
25. Cystic Fibrosis
CLINICAL MANIFESTATIONS
DIAGNOSIS
PATHOGENESIS
SPECIFIC PATHOGENS
ANAEROBIC BACTERIA
TREATMENT OF PATHOGENS IN PATIENTS WITH CYSTIC FIBROSIS
TREATMENT OF PULMONARY EXACERBATIONS
COVID-19
CONCLUSION
Section 3. Infections of the Heart
26. Infective Endocarditis
EPIDEMIOLOGY
PATHOPHYSIOLOGY
CLINICAL MANIFESTATIONS
LABORATORY FINDINGS
MICROBIOLOGY
TREATMENT
PREVENTION
27. Infectious Pericarditis
ANATOMY AND FUNCTION
BACTERIAL PERICARDITIS
VIRAL PERICARDITIS
28. Myocarditis
EPIDEMIOLOGY
ETIOLOGIES
PATHOLOGY
PATHOGENESIS
PATHOPHYSIOLOGY
CLINICAL MANIFESTATIONS
DIAGNOSIS
MOLECULAR DIAGNOSTIC STUDIES
DIFFERENTIAL DIAGNOSIS
TREATMENT
PROGNOSIS
MYOCARDITIS IN CASES OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION
PARASITIC MYOCARDITIS
29. Acute Rheumatic Fever
EPIDEMIOLOGY
PATHOGENESIS
VACCINE DEVELOPMENT
RHEUMATIC FEVER IN DEVELOPING COUNTRIES
PATHOLOGY
CLINICAL COURSE
LABORATORY FINDINGS
DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
TREATMENT
CARDIAC SURGERY
PROGNOSIS
PREVENTION OF RHEUMATIC FEVER
SECONDARY PREVENTION OF RHEUMATIC FEVER
THE GLOBAL COVID-19 PANDEMIC AND RHEUMATIC FEVER
CONCLUSION
30. Mediastinitis
ACUTE MEDIASTINITIS
CHRONIC MEDIASTINITIS
Section 4. Central Nervous System Infections
31. Bacterial Meningitis Beyond the Neonatal Period
INCIDENCE AND EPIDEMIOLOGY
PATHOPHYSIOLOGY
PATHOGENESIS
PATHOLOGY
CLINICAL MANIFESTATIONS AND PATHOPHYSIOLOGIC RELATIONSHIPS
DIFFERENTIAL DIAGNOSIS
DIAGNOSIS
TREATMENT
PROGNOSIS AND SEQUELAE
PREVENTION
32. Parameningeal Infections
BRAIN ABSCESS
SUBDURAL EMPYEMA
EPIDURAL ABSCESS
SPINAL EPIDURAL INFECTIONS
33. Fungal Meningitis
EPIDEMIOLOGY
DIAGNOSIS
CLINICAL MANIFESTATIONS
34. Eosinophilic Meningitis
INTRODUCTION
EPIDEMIOLOGY
PATHOGENESIS
CLINICAL MANIFESTATIONS
DIAGNOSIS
TREATMENT
COURSE AND PROGNOSIS
PREVENTION
35. Aseptic Meningitis and Viral Meningitis
HISTORY
ETIOLOGY
EPIDEMIOLOGY
CLINICAL MANIFESTATIONS
DIFFERENTIAL DIAGNOSIS
SPECIFIC DIAGNOSIS
TREATMENT
PROGNOSIS
PREVENTION
36. Encephalitis and Meningoencephalitis
HISTORY
ETIOLOGY
EPIDEMIOLOGY
PATHOGENESIS
PATHOLOGY
CLINICAL MANIFESTATIONS
DIFFERENTIAL DIAGNOSIS
EVALUATION OF A PATIENT WITH ENCEPHALOPATHY OR POSSIBLE ENCEPHALITIS
DIAGNOSIS
TREATMENT
PROGNOSIS
PREVENTION
37. Parainfectious and Postinfectious Demyelinating Disorders of the Central Nervous System
ACUTE DISSEMINATED ENCEPHALOMYELITIS
38. Infection-Associated Myelitis and Myelopathies of the Spinal Cord
ACUTE TRANSVERSE MYELITIS
DIAGNOSTIC CRITERIA
EPIDEMIOLOGY
CLINICAL PRESENTATION
RADIOLOGIC FEATURES
LUMBAR PUNCTURE
DIFFERENTIAL DIAGNOSIS
TREATMENT
OUTCOME AND PROGNOSIS
39. Guillain-Barré Syndrome
EPIDEMIOLOGY
CLINICAL MANIFESTATIONS
SUBTYPES
DIFFERENTIAL DIAGNOSIS
PATHOGENESIS
CLINICAL EVALUATION
TREATMENT
OUTCOME AND PROGNOSIS
Section 5. Genitourinary Tract Infections
40. Urethritis
EPIDEMIOLOGY
PATHOPHYSIOLOGY
CLINICAL PRESENTATION
DIFFERENTIAL DIAGNOSIS
SPECIFIC DIAGNOSIS
TREATMENT
PROGNOSIS
PREVENTION
41. Cystitis and Pyelonephritis
EPIDEMIOLOGY
RISK FOR URINARY TRACT INFECTION
RISK FACTORS FOR URINARY TRACT INFECTION
PATHOGENESIS
CLINICAL PRESENTATION
DIFFERENTIAL DIAGNOSIS
DIAGNOSIS
TREATMENT
PROGNOSIS
PREVENTION
42. Renal Abscess
CLINICAL FINDINGS
DIAGNOSTIC EVALUATION
THERAPEUTIC CONSIDERATIONS
43. Prostatitis
CONCLUSION
44. Female Genital Infections
GENERAL APPROACH TO EVALUATION
NORMAL VAGINAL FLORA
LOWER GENITAL TRACT INFECTIONS
SPECIFIC SEXUALLY TRANSMITTED VULVOVAGINITIS
VULVOVAGINAL LESIONS, ULCERATIONS, AND GRANULOMATOUS INFECTIONS
Cervicitis
UPPER GENITAL TRACT INFECTIONS
Section 6. Gastrointestinal Tract Infections
45. Esophagitis
PATHOPHYSIOLOGY AND CAUSATIVE ORGANISMS
CLINICAL FEATURES
DIFFERENTIAL DIAGNOSIS
DIAGNOSIS
PREVENTION
TREATMENT
PROGNOSIS
46. Approach to Patients With Gastrointestinal Tract Infections and Food Poisoning
EPIDEMIOLOGY
CLINICAL CLASSIFICATION OF DIARRHEA EPISODES
ORGANISMS THAT CAUSE DIARRHEA
DIAGNOSIS
TREATMENT
PREVENTION
COVID-19 AND GASTROINTESTINAL MANIFESTATIONS
47. Clostridioides difficile Infection
HISTORY
EPIDEMIOLOGY
PATHOGENESIS
CLINICAL MANIFESTATIONS
LABORATORY STUDIES
DIFFERENTIAL DIAGNOSIS
TREATMENT
PREVENTION AND CONTROL
48. Whipple Disease
HISTORY
EPIDEMIOLOGY
ETIOLOGY AND PATHOGENESIS
CLINICAL MANIFESTATIONS
ACUTE INFECTION
DIAGNOSIS
TREATMENT
CONCLUSION
Section 7. Liver Diseases
49. Hepatitis
HISTORY
CLINICAL MANIFESTATIONS AND EVALUATION
INFECTIOUS CAUSES
NONINFECTIOUS CAUSES
50. Cholangitis and Cholecystitis
CHOLANGITIS
ETIOLOGY AND PATHOGENESIS
CLINICAL PRESENTATION
DIAGNOSTIC EVALUATION
DIFFERENTIAL DIAGNOSIS
TREATMENT
PREVENTION
COMPLICATIONS OF CHOLANGITIS
SPECIFIC POPULATIONS AND CHOLANGITIS
CHOLECYSTITIS
51. Pyogenic Liver Abscess
PATHOGENESIS
MICROBIOLOGY
CLINICAL MANIFESTATIONS
DIAGNOSIS
TREATMENT
COMPLICATIONS AND PROGNOSIS
52. Reye Syndrome
EPIDEMIOLOGY
CLINICAL MANIFESTATIONS AND LABORATORY FINDINGS
TREATMENT AND PREVENTION
Section 8. Other Intraabdominal Infections
53. Appendicitis and Pelvic Abscess
EPIDEMIOLOGY
PATHOPHYSIOLOGY
CLINICAL MANIFESTATIONS
DIAGNOSIS
MICROBIOLOGY
TREATMENT
PROGNOSIS AND RELEVANT INFECTIOUS COMPLICATIONS
PELVIC ABSCESS
54. Pancreatitis
CLINICAL MANIFESTATIONS
DIAGNOSIS
CAUSES
INFECTIOUS CAUSES
PATHOGENESIS
TREATMENT
COMPLICATIONS
55. Peritonitis and Intraabdominal Abscess
PERITONITIS
INTRAABDOMINAL ABSCESS
56. Retroperitoneal Infections
ETIOLOGY AND PATHOGENESIS
MICROBIOLOGY
CLINICAL PRESENTATION
DIFFERENTIAL DIAGNOSIS
SPECIFIC DIAGNOSIS
TREATMENT
PROGNOSIS
Section 9. Musculoskeletal Infections
57. Osteomyelitis
INTRODUCTION
ETIOLOGY OF ACUTE HEMATOGENOUS OSTEOMYELITIS IN CHILDREN IN MICROBIOLOGICALLY CONFIRMED CASES
HEMATOGENOUS OSTEOMYELITIS
Differential Diagnosis
NONHEMATOGENOUS OSTEOMYELITIS
UNUSUAL MICROBIAL CAUSES OF OSTEOMYELITIS
CHRONIC OSTEOMYELITIS
58. Septic Arthritis
EPIDEMIOLOGY
PATHOPHYSIOLOGY
ETIOLOGY
DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
TREATMENT
PROGNOSIS
SPECIAL PROBLEMS
59. Bacterial Myositis and Pyomyositis
PYOMYOSITIS
ACUTE BACTERIAL MYOSITIS
MISCELLANEOUS CAUSES OF MYOSITIS
Section 10. Skin Infections
60. Cutaneous Manifestations of Systemic Infections
HISTORY
ETIOLOGIC AGENTS
EPIDEMIOLOGY
PATHOPHYSIOLOGY AND PATHOLOGY OF EXANTHEMS
CLINICAL MANIFESTATIONS
DIAGNOSIS
TREATMENT, PROGNOSIS, AND PREVENTION
61. Roseola Infantum (Exanthem Subitum)
HISTORY
EPIDEMIOLOGY
ETIOLOGY
PATHOPHYSIOLOGY
CLINICAL PRESENTATION
CLINICAL COMPLICATIONS
DIAGNOSIS
TREATMENT AND PROGNOSIS
62. Bacterial Skin Infections
NORMAL SKIN
CUTANEOUS INFECTION AND DERMATOLOGIC MANIFESTATIONS OF SYSTEMIC DISEASE
IMPETIGO
PERIANAL STREPTOCOCCAL DERMATITIS
BLISTERING DISTAL DACTYLITIS
ERYSIPELAS
ECTHYMA
FOLLICULITIS, FURUNCULOSIS, AND CARBUNCLES
HIDRADENITIS SUPPURATIVA
CELLULITIS
NECROTIZING FASCIITIS
CONTAMINATED WOUNDS
63. Viral and Fungal Skin Infections
VIRAL INFECTIONS
FUNGAL INFECTIONS
Section 11. Ocular Infectious Diseases
64. Ocular Infections
INFECTIONS OF THE EYELIDS
ANTERIOR EYELID INFECTION
CONJUNCTIVAL INFECTIONS
KERATITIS: CORNEAL INFLAMMATION
INFECTIONS PRIMARILY INVOLVING THE UVEA
INFECTIONS INVOLVING PRIMARILY THE RETINA
Section 12. Systemic Infectious Diseases
65. Bacteremia and Septic Shock
PATHOPHYSIOLOGY
CLINICAL PRESENTATION AND DIAGNOSIS
TREATMENT
INVESTIGATIVE THERAPIES
PROGNOSIS
66. Fever Without Source and Fever of Unknown Origin
FEVER WITHOUT SOURCE
FEVER OF UNKNOWN ORIGIN
Acknowledgments
67. Toxic Shock Syndrome
EPIDEMIOLOGY
HISTOPATHOLOGY
CLINICAL SPECTRUM
DIFFERENTIAL DIAGNOSIS
PREVENTION AND PROPHYLAXIS
Section 13. Infections of the Fetus and Newborn
68. Approach to Infections in the Fetus and Newborn
VIRAL INFECTIONS OF THE FETUS AND NEONATE
BACTERIAL DISEASES OF THE FETUS AND NEWBORN
YEAST AND FUNGAL INFECTIONS OF THE FETUS AND NEONATE
CONGENITAL TOXOPLASMOSIS
CHLAMYDIA, MYCOPLASMA, AND UREAPLASMA INFECTIONS IN THE NEONATE
CONGENITAL SYPHILIS
Section 14. Infections of the Compromised Host
69. Inborn Errors of Immunity (Primary Immunodeficiencies)
DEFINITIONS AND INTRODUCTION
EVALUATION FOR SUSPECTED IMMUNODEFICIENCY
Principles of Management of Primary Immunodeficiencies
ASSOCIATIONS BETWEEN SPECIFIC PATHOGENS AND PIDDS
SELECTED IMMUNODEFICIENCIES AFFECTING CELLULAR AND HUMORAL IMMUNITY
SELECTED COMBINED IMMUNODEFICIENCIES WITH ASSOCIATED OR SYNDROMIC FEATURES
SELECTED PREDOMINANTLY ANTIBODY DEFICIENCIES
IgG SUBCLASS “DEFICIENCY”
SELECTED CONGENITAL DEFECTS OF PHAGOCYTE NUMBER OR FUNCTION
SELECTED DEFECTS IN INTRINSIC AND INNATE IMMUNITY
COMPLEMENT DEFICIENCIES
CONCLUSION
70. The Febrile Neutropenic Patient
EPIDEMIOLOGY OF FEVER AND NEUTROPENIA
FEVER AND NEUTROPENIA OF UNKNOWN ORIGIN
RISK STRATIFICATION
HISTORY AND PHYSICAL EXAMINATION
INITIAL DIAGNOSTIC EVALUATION
INITIAL THERAPY FOR FEVER AND NEUTROPENIA
DIAGNOSTIC EVALUATION FOR PROLONGED FEVER AND NEUTROPENIA
THERAPEUTIC ADJUSTMENTS FOR PROLONGED FEVER AND NEUTROPENIA
PREVENTION MEASURES
71. Opportunistic Infections in Hematopoietic Stem Cell Transplantation
EPIDEMIOLOGY
MAJOR TYPES OF OPPORTUNISTIC INFECTIONS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
VACCINATIONS AFTER HEMATOPOIETIC STEM CELL TRANSPLANT
72. Infections in Pediatric Heart Transplantation
PRETRANSPLANT EVALUATION
SURGICAL PROPHYLACTIC ANTIBIOTICS
IMMUNOSUPPRESSION
IMMEDIATE POSTOPERATIVE INFECTIONS
INFECTIONS BETWEEN THE FIRST AND SIXTH POSTOPERATIVE MONTHS
INFECTIONS AFTER THE SIXTH POSTOPERATIVE MONTH
GASTROINTESTINAL INFECTIONS
CORONAVIRUS DISEASE 2019 (COVID-19)
OTHER VIRUSES
CENTRAL NERVOUS SYSTEM INFECTIONS
IMMUNOSUPPRESSIVE AGENTS AND ANTIBIOTICS
IMMUNIZATIONS
73. Infections in Pediatric Lung Transplantation
INTRODUCTION
Timing of Infection After Transplant
PRETRANSPLANT EVALUATION
SELECTED PATHOGENS
74. Opportunistic Infections in Liver and Intestinal Transplantation
PREDISPOSING FACTORS
TIMING OF INFECTIONS
BACTERIAL AND FUNGAL INFECTIONS
VIRAL INFECTIONS
OPPORTUNISTIC INFECTIONS
MANAGEMENT
CONCLUSION
75. Infections in Renal Transplantation
PRETRANSPLANT EVALUATION
POSTTRANSPLANT INFECTIOUS COMPLICATIONS
CONCLUSION
76. Infections Related to Prosthetic or Artificial Devices
INTERACTION OF THE HOST WITH A PROSTHETIC DEVICE
INTERACTION OF MICROORGANISMS WITH A PROSTHETIC DEVICE
TISSUE EXPANDERS
COCHLEAR IMPLANTS
OCULAR PROSTHESES
LEFT VENTRICULAR ASSIST DEVICES
EXTRACORPOREAL MEMBRANE OXYGENATION CIRCUITS
PERMANENT CARDIAC PACEMAKER AND IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR INFECTIONS
PROSTHETIC JOINT AND ORTHOPEDIC IMPLANT INFECTIONS
CEREBROSPINAL FLUID SHUNTS
INTRACRANIAL PRESSURE MONITORS
INTRATHECAL PUMP INFUSION DEVICES
77. Infections in Burn Patients
BURN WOUND
INFLAMMATORY AND IMMUNE RESPONSES IN BURNS
BURN WOUND MICROBIOLOGY
CLINICAL MANIFESTATIONS
MICROBIOLOGIC INVESTIGATIONS
PREVENTION AND TREATMENT OF INFECTION
INFECTION CONTROL
Section 15. Unclassified Infectious Diseases
78. Kawasaki Disease
HISTORY
EPIDEMIOLOGY
ETIOLOGY
Genetic Susceptibility
PATHOLOGY AND PATHOGENESIS
CLINICAL MANIFESTATIONS
INCOMPLETE KAWASAKI DISEASE
DIFFERENTIAL DIAGNOSIS
LABORATORY FINDINGS
MANAGEMENT
COMPLICATIONS
LONG-TERM FOLLOW-UP AND PROGNOSIS
79. Chronic Fatigue Syndrome (Systemic Exertion Intolerance Disease)
HISTORICAL OVERVIEW
EPIDEMIOLOGY
ETIOLOGY AND PATHOGENESIS
CLINICAL MANIFESTATIONS
DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS
MANAGEMENT
PROGNOSIS AND FUTURE DIRECTIONS
Part III. Infections With Specific Microorganisms
Bacterial Infections
VOLUME TWO
Viral Infections
Subsection I. DNA—Parvoviridae
152. Human Parvovirus B19
HISTORY
PROPERTIES OF THE VIRUS
EPIDEMIOLOGY
PATHOGENESIS AND PATHOLOGY
CLINICAL MANIFESTATIONS
DIFFERENTIAL DIAGNOSIS
DIAGNOSIS
TREATMENT AND PROGNOSIS
PREVENTION
153. Human Bocaviruses
HISTORY
PROPERTIES
EPIDEMIOLOGY
IMPACT OF THE COVID-19 PANDEMIC ON HBoV
PATHOGENESIS
CLINICAL MANIFESTATIONS
DIAGNOSIS
TREATMENT
PROGNOSIS
Subsection II. DNA—Polyomaviridae
154. Human Polyomaviruses
HISTORY
VIROLOGY
EPIDEMIOLOGY
CLINICAL MANIFESTATIONS
LABORATORY DIAGNOSIS
TREATMENT AND PREVENTION
155. Human Papillomaviruses
HISTORY
VIROLOGY
EPIDEMIOLOGY
CLINICAL MANIFESTATIONS
LABORATORY DIAGNOSIS
TREATMENT
PREVENTION
FUTURE DIRECTIONS
Subsection III. DNA—Adenoviridae
156. Adenoviruses
HISTORY
PROPERTIES OF THE VIRUS
EPIDEMIOLOGY
PATHOGENESIS AND PATHOLOGY
CLINICAL MANIFESTATIONS
DIAGNOSIS
TREATMENT
PREVENTION
PROGNOSIS
Subsection IV. DNA—Hepatoviridae
157. Hepatitis B and D Viruses
Hepatitis B Virus
Hepatitis D Virus
Acknowledgment
Subsection V. DNA—Herpesviridae
158. Herpes Simplex Viruses 1 and 2
THE VIRUSES
TRANSMISSION
EPIDEMIOLOGY
PATHOGENESIS AND PATHOLOGY
CLINICAL MANIFESTATIONS
DIAGNOSIS
PROGNOSIS, COMPLICATIONS, AND SEQUELAE
POSTINFECTIOUS ENCEPHALITIS
TREATMENT
Acknowledgments
159. Cytomegalovirus
HISTORY
VIROLOGY
EPIDEMIOLOGY
PATHOLOGY, PATHOGENESIS, AND IMMUNITY
CLINICAL MANIFESTATIONS
LABORATORY DIAGNOSIS
TREATMENT
PREVENTION
160. Epstein-Barr Virus
HISTORY
VIROLOGY
IMMUNOPATHOGENESIS
HISTOPATHOLOGY
EPIDEMIOLOGY
TRANSMISSION
NONMALIGNANT CLINICAL SYNDROMES ASSOCIATED WITH EBV INFECTION
COMPLICATIONS OF INFECTIOUS MONONUCLEOSIS
MALIGNANT DISEASES ASSOCIATED WITH EPSTEIN-BARR VIRUS
DIAGNOSIS OF INFECTIOUS MONONUCLEOSIS
TREATMENT
PROGNOSIS
PREVENTION
161. Human Herpesviruses 6A, 6B, 7, and 8
HUMAN HERPESVIRUSES 6A, 6B, AND 7
KAPOSI SARCOMA HERPESVIRUS (HUMAN HERPESVIRUS-8)
162. Varicella Zoster Virus
THE ORGANISM
TRANSMISSION
EPIDEMIOLOGY
PATHOGENESIS
NOSOCOMIAL VARICELLA
CLINICAL MANIFESTATIONS
DIAGNOSIS
TREATMENT
PROGNOSIS
PREVENTION
Subsection VI. DNA—Poxviridae
163. Smallpox (Variola Virus)
HISTORY
ETIOLOGY
EPIDEMIOLOGY
PATHOLOGY
CLINICAL MANIFESTATIONS
DIFFERENTIAL DIAGNOSIS
SPECIFIC DIAGNOSIS
TREATMENT
PREVENTION
164. Monkeypox and Other Poxviruses
PROPERTIES OF THE VIRUSES
SPECIFIC VIRUSES AND THEIR ILLNESSES
DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS
165. Mimiviruses
STRUCTURE AND PROPERTIES
VIRAL REPLICATION
ANIMAL SUSCEPTIBILITY
MIMIVIRUS INFECTION IN HUMANS
DIAGNOSTIC METHODS
MIMIVIRUS AS AN EMERGING PATHOGEN
TREATMENT AND PREVENTION
Acknowledgment
Subsection I. RNA—Picornaviridae
166. Enteroviruses, Parechoviruses, and Saffold Viruses
HISTORY
THE VIRUSES
EPIDEMIOLOGY
PATHOGENESIS
PATHOLOGY
CLINICAL MANIFESTATIONS: NONPOLIO ENTEROVIRUSES, PARECHOVIRUSES, AND SAFFOLD VIRUSES
NEONATAL INFECTIONS
CLINICAL MANIFESTATIONS: POLIOVIRUS
DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS
TREATMENT
PREVENTION
Acknowledgments
167. Rhinoviruses
HISTORY
ORGANISM
EPIDEMIOLOGY
PERSON-TO-PERSON TRANSMISSION
PATHOGENESIS AND HOST FACTORS
CLINICAL MANIFESTATIONS
DIAGNOSIS OF INFECTION
PREVENTION AND TREATMENT
Acknowledgments
168. Hepatitis A Virus
INTRODUCTION
EPIDEMIOLOGY
VIROLOGY
PREVENTION
TREATMENT
SUMMARY
Subsection II. RNA—Caliciviridae
169. Caliciviruses
VIROLOGIC FEATURES
EPIDEMIOLOGY
PATHOGENESIS
IMMUNE RESPONSE
CLINICAL MANIFESTATIONS
DIFFERENTIAL DIAGNOSIS
DIAGNOSIS
TREATMENT AND PREVENTION
PROGNOSIS
170. Hepatitis E Virus
HISTORY AND DISCOVERY OF VIRUS
MICROBIOLOGY AND GENOME ORGANIZATION
EPIDEMIOLOGY
PATHOGENESIS AND IMMUNITY
CLINICAL MANIFESTATIONS
DIAGNOSTIC TESTING
DISEASE PREVENTION AND VACCINE CANDIDATES
SUMMARY
Subsection III. RNA—Reoviridae
171. Reoviruses
HISTORY
PROPERTIES
EPIDEMIOLOGY
CLINICAL MANIFESTATIONS
DIAGNOSIS
172. Orbiviruses, Coltiviruses, and Seadornaviruses: Colorado Tick Fever, Banna Virus, and Others
COLORADO TICK FEVER VIRUS
BANNA VIRUS
KEMEROVO AND RELATED VIRUSES
ORUNGO VIRUS
LEBOMBO VIRUS
CHANGUINOLA VIRUS
Acknowledgment
173. Rotavirus
ROTAVIRUSES
ROTAVIRUS INFECTION
ROTAVIRUS DISEASE
EPIDEMIOLOGY
LABORATORY DIAGNOSIS
TREATMENT
ROTAVIRUS IMMUNITY
ROTAVIRUS VACCINES
Subsection IV. RNA—Togaviridae
174. Rubella Virus
HISTORY
PROPERTIES
EPIDEMIOLOGY
PATHOLOGY AND PATHOGENESIS
CLINICAL MANIFESTATIONS
DIAGNOSIS
TREATMENT
PREVENTION
175. Eastern Equine Encephalitis
ETIOLOGIC AGENT
ECOLOGY
EPIDEMIOLOGY
PATHOLOGY
PATHOGENESIS
CLINICAL MANIFESTATIONS
PROGNOSIS AND SEQUELAE
DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
TREATMENT
PREVENTION
Acknowledgment
176. Western Equine Encephalitis
ETIOLOGIC AGENT
ECOLOGY
EPIDEMIOLOGY
CLINICAL MANIFESTATIONS
PATHOLOGY
PATHOGENESIS
PROGNOSIS
DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
TREATMENT
PREVENTION
Acknowledgment
177. Venezuelan Equine Encephalitis
ETIOLOGIC AGENT
EPIDEMIOLOGY AND ECOLOGY
CLINICAL MANIFESTATIONS
PATHOLOGY AND PATHOGENESIS
LABORATORY DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
TREATMENT
PREVENTION
Acknowledgment
178. Chikungunya
ETIOLOGIC AGENT
ZOONOTIC CYCLES
EPIDEMIOLOGY
CLINICAL MANIFESTATIONS
PATHOGENESIS AND PATHOLOGY
DIAGNOSIS
TREATMENT
PROGNOSIS
PREVENTION
179. Ross River Virus Arthritis
ETIOLOGIC AGENT
TRANSMISSION AND EPIDEMIOLOGY
CLINICAL MANIFESTATIONS
PATHOLOGY
DIAGNOSIS
TREATMENT AND PROGNOSIS
PREVENTION
Acknowledgments
180. Other Alphaviral Infections
O’NYONG-NYONG
IGBO-ORA FEVER
BARMAH FOREST FEVER
SINDBIS FEVER
MAYARO FEVER
SEMLIKI FOREST VIRUS FEVER
Acknowledgment
Subsection V. Flaviviridae
181. St. Louis Encephalitis
ETIOLOGIC AGENT
ECOLOGY
EPIDEMIOLOGY
CLINICAL MANIFESTATIONS
PATHOLOGY
PATHOGENESIS
DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
TREATMENT
PROGNOSIS
PREVENTION
Acknowledgment
182. West Nile Virus
History
Virology
Epidemiology
Pathogenesis
Clinical Manifestations
Outcome
Laboratory Findings
Electrodiagnostic Studies
Neuroimaging
Viral Culture And Nucleic Acid Amplification Detection of West Nile Virus
Detection of West Nile Virus–Specific Antibodies
Neuropathology
Treatment
Prevention
Acknowledgment
183. Yellow Fever
HISTORY
ETIOLOGIC AGENT
EPIDEMIOLOGY
CLINICAL MANIFESTATIONS
PATHOLOGY
LABORATORY FINDINGS
DIFFERENTIAL DIAGNOSIS
LABORATORY DIAGNOSIS
TREATMENT
PROGNOSIS
PREVENTION AND CONTROL
184. Dengue, Dengue Hemorrhagic Fever, and Severe Dengue
ETIOLOGIC AGENTS
TRANSMISSION
HISTORY
EPIDEMIOLOGY
CLINICAL MANIFESTATIONS
PATHOLOGY AND PATHOGENESIS
DIAGNOSIS
LABORATORY STUDIES
TREATMENT
REGULATORY MEASURES
PROGNOSIS
PREVENTION
185. Japanese Encephalitis
HISTORY
ETIOLOGIC AGENT
EPIDEMIOLOGY
CLINICAL MANIFESTATIONS
PATHOLOGY
PATHOPHYSIOLOGY
COMPLICATIONS
LABORATORY DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
TREATMENT
PROGNOSIS
PREVENTION
186. Murray Valley Encephalitis
ETIOLOGIC AGENT
TRANSMISSION AND EPIDEMIOLOGY
CLINICAL MANIFESTATIONS
PATHOLOGY
DIAGNOSIS
TREATMENT AND PROGNOSIS
PREVENTION
187. Tick-Borne Encephalitis
HISTORY
ETIOLOGIC AGENT
ECOLOGY
EPIDEMIOLOGY
CLINICAL MANIFESTATIONS
PATHOLOGY
PATHOGENESIS
LABORATORY DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
TREATMENT
PROGNOSIS
PREVENTION
188. Zika Virus Infections
EPIDEMIOLOGY
VIROLOGY AND PATHOGENESIS
CLINICAL MANIFESTATIONS AND COMPLICATIONS
ZIKV DIAGNOSIS, MANAGEMENT, THERAPEUTICS, AND PREVENTION
EVALUATION AND MANAGEMENT OF PEDIATRIC PATIENTS WITH ZIKV
ZIKV PREVENTION: VECTOR CONTROL, VACCINES, AND OTHER CHALLENGES
CONCLUSION
189. Other Less Commonly Recognized Flaviviruses
Powassan Viral Encephalitis
Rocio Viral Encephalitis
Louping Ill Virus
Kyasanur Forest Disease
Omsk Hemorrhagic Fever
Other Flaviviral Infections
190. Hepatitis C Virus
HISTORY
VIROLOGY
PATHOGENESIS
VIRAL LIFE CYCLE
EPIDEMIOLOGY
VIRAL GENETICS
TRANSMISSION
CLINICAL MANIFESTATIONS
IMMUNITY
DIAGNOSIS
TREATMENT
PREVENTION AND COUNSELING
SUMMARY
Subsection VI. Orthomyxoviridae
191. Influenza Viruses
HISTORY
BIOLOGY
ECOLOGY
SURVEILLANCE
EVOLUTION AND ADAPTATION
EPIDEMIOLOGY
CLINICAL MANIFESTATIONS
PATHOLOGY
PATHOGENESIS
DIAGNOSIS
MANAGEMENT
INFECTION CONTROL
VACCINES
EFFICACY AND EFFECTIVENESS
PANDEMIC PREPAREDNESS
Subsection VII. Paramyxoviridae
192. Parainfluenza Viruses
HISTORY
CHARACTERIZATION OF PARAINFLUENZA VIRUSES
EPIDEMIOLOGY
PATHOGENESIS
IMMUNE RESPONSE: ROLE IN PATHOGENESIS AND PROTECTION
CLINICAL MANIFESTATIONS
DIAGNOSIS
MANAGEMENT AND THERAPY
PROGNOSIS
PREVENTION
193. Measles Virus
HISTORY
PROPERTIES
EPIDEMIOLOGY
PATHOGENESIS AND PATHOLOGY
CLINICAL MANIFESTATIONS
DIFFERENTIAL DIAGNOSIS
DIAGNOSIS
TREATMENT
PREVENTION
194. Mumps Virus
HISTORY
CLASSIFICATION
PROPERTIES
EPIDEMIOLOGY
PATHOGENESIS
PATHOLOGY
CLINICAL MANIFESTATIONS
DIFFERENTIAL DIAGNOSIS
DIAGNOSIS
TREATMENT
PROGNOSIS
PREVENTION
195. Respiratory Syncytial Virus
HISTORY
STRUCTURAL AND ANTIGENIC PROPERTIES
EPIDEMIOLOGY
PATHOLOGY AND PATHOGENESIS
IMMUNITY AND DISEASE PATHOGENESIS
CLINICAL MANIFESTATIONS
PROGNOSIS
DIAGNOSIS
TREATMENT
PREVENTION
Acknowledgment
196. Human Metapneumovirus
HISTORY
PROPERTIES
EPIDEMIOLOGY
PATHOGENESIS AND PATHOLOGY
CLINICAL MANIFESTATIONS
DIFFERENTIAL DIAGNOSIS
DIAGNOSIS
TREATMENT
PROGNOSIS
PREVENTION
Subsection VIII. Rhabdoviridae
197. Rabies Virus
HISTORY
ETIOLOGY
TRANSMISSION AND EPIDEMIOLOGY
COVID-19 AND RABIES
PATHOBIOLOGY
CLINICAL MANIFESTATIONS
DIAGNOSIS
PROPHYLAXIS
PREEXPOSURE IMMUNIZATION
FUTURE DEVELOPMENTS
Acknowledgments
Subsection IX. Arenaviridae and Filoviridae
198. Lymphocytic Choriomeningitis Virus
HISTORY
EPIDEMIOLOGY
CLINICAL MANIFESTATIONS
DIAGNOSIS
TREATMENT
CONCLUSION
199. Arenaviral Hemorrhagic Fevers
HISTORY
ETIOLOGIC AGENTS
Person-to-Person Transmission
CLINICAL MANIFESTATIONS
PATHOGENESIS AND PATHOLOGY
DIAGNOSIS
PROGNOSIS AND TREATMENT
PREVENTION AND CONTROL
Acknowledgment
200. Filoviral Hemorrhagic Fever: Marburg and Ebola Virus Fevers
ETIOLOGIC AGENTS
HISTORY AND EPIDEMIOLOGY
CLINICAL MANIFESTATIONS
PATHOLOGY
DIFFERENTIAL DIAGNOSIS
DIAGNOSIS
INFECTION CONTROL, PREVENTION, AND TREATMENT
CONCLUSION
Subsection X. Coronaviridae and Torovirdae
201. Human Coronaviruses
BACKGROUND
VIROLOGY
EPIDEMIOLOGY OF COMMON COLD RESPIRATORY CORONAVIRUSES
INFECTION AND IMMUNITY
CLINICAL MANIFESTATIONS OF RESPIRATORY TRACT INFECTIONS
LABORATORY DIAGNOSIS
PREVENTION AND TREATMENT
SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2
Subsection XI. Bunyaviridae
202. Hantaviruses
Historical Perspective
Organism
Epidemiology
Clinical Manifestations
Complications
Pathogenesis And Pathology
Diagnosis And Differential Diagnosis
Treatment
Prevention
203. La Crosse Virus and Other California Serogroup Viruses
ETIOLOGIC AGENT
ECOLOGY
EPIDEMIOLOGY
PATHOGENESIS
CLINICAL MANIFESTATIONS
LABORATORY AND RADIOLOGIC DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
TREATMENT
OUTCOME
PATHOLOGY
PREVENTION
204. Rift Valley Fever
HISTORY
ETIOLOGIC AGENT
VECTORS AND EPIDEMIOLOGY
CLINICAL MANIFESTATIONS
LABORATORY FINDINGS
TREATMENT
PREVENTION
205. Crimean-Congo Hemorrhagic Fever
ETIOLOGIC AGENT
EPIDEMIOLOGY
PATHOGENESIS
CLINICAL MANIFESTATIONS
DIAGNOSIS
TREATMENT
PROGNOSIS
PREVENTION
206. Phlebotomus Fever (Sandfly Fever)
ETIOLOGIC AGENT
EPIDEMIOLOGY
CLINICAL MANIFESTATIONS
PATHOLOGY
DIAGNOSIS
TREATMENT
PROGNOSIS
PREVENTION
Acknowledgment
207. Oropouche Fever
ETIOLOGIC AGENT AND MOLECULAR AND SEROLOGIC CLASSIFICATION
EPIDEMIOLOGY
CLINICAL MANIFESTATIONS
PATHOGENESIS
LABORATORY FINDINGS
DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
TREATMENT
PREVENTION AND CONTROL
208. Toscana Virus
HISTORY
ETIOLOGIC AGENT
EPIDEMIOLOGY
CYCLE IN NATURE
CLINICAL MANIFESTATIONS
DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS
GENETIC DIVERSITY OF TOSCANA VIRUS
Subsection XII. Retroviridae
209. Oncoviruses (Human T-Cell Lymphotropic Viruses) and Lentiviruses (Human Immunodeficiency Virus Type 2)
CLASSIFICATION
ONCOVIRUSES: HUMAN T-CELL LYMPHOTROPIC VIRUS TYPES
LENTIVIRUSES: HUMAN IMMUNODEFICIENCY VIRUS TYPE 2
210. Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome
Epidemiology of Pediatric HIV Infection
Staging of Pediatric HIV Infection
Transmission And Prevention
Etiology
Pathogenesis
Clinical Manifestations
Complications
Diagnosis of HIV Infection In Infants And Children
Immunologic And Clinical Monitoring of Children Living With HIV
Treatment
CAPSID INHIBITORS
Subsection XIII. Prion-Related Diseases
211. Transmissible Spongiform Encephalopathies (Creutzfeldt-Jakob Disease, Gerstmann-Sträussler-Scheinker Disease, Kuru, Fatal Familial Insomnia, New Variant Creutzfeldt-Jakob Disease, Sporadic Fatal Insomnia, Variably Protease Sensitive Prionopathy)
HISTORY
EPIDEMIOLOGY AND NATURAL HISTORY
ETIOLOGIC AGENT AND PATHOGENESIS
PATHOLOGY
CLINICAL MANIFESTATIONS
DIAGNOSIS
TREATMENT
PREVENTION
Section 18. Chlamydia
212. Chlamydia Infections
Infections Caused by Chlamydia trachomatis
Infection Caused by Chlamydia pneumoniae
Section 19. Rickettsial Diseases
213. Rickettsial and Ehrlichial Diseases
SPOTTED FEVERS
TYPHUS
EHRLICHIOSIS AND ANAPLASMOSIS
Section 20. Mycoplasma
214. Mycoplasma and Ureaplasma Infections
HISTORY
CLASSIFICATION
MYCOPLASMOIDES PNEUMONIAE
UREAPLASMA
METAMYCOPLASMA HOMINIS
MYCOPLASMOIDES GENITALIUM
MYCOPLASMOPSIS FERMENTANS
MALACOPLASMA PENETRANS
DIAGNOSIS OF GENITAL MYCOPLASMAS
OTHER MYCOPLASMA SPECIES AND MYCOPLASMA RELATIONSHIPS
TREATMENT OF GENITAL MYCOPLASMAS
PREVENTION OF GENITAL MYCOPLASMAS
Section 21. Fungal Diseases
215. Aspergillosis
ORGANISM
CLINICAL PRESENTATIONS
EPIDEMIOLOGY
DIAGNOSIS
TREATMENT
216. Blastomycosis
HISTORICAL PERSPECTIVE
MYCOLOGY
ECOLOGY AND EPIDEMIOLOGY
PATHOGENESIS
CLINICAL MANIFESTATIONS
DIAGNOSIS
TREATMENT
217. Candidiasis
ORGANISM
EPIDEMIOLOGY
RISK FACTORS
PATHOGENESIS
CLINICAL MANIFESTATIONS
DIAGNOSIS
ANTIFUNGAL PROPHYLAXIS AND TREATMENT
NEONATAL CANDIDIASIS
218. Coccidioidomycosis
EPIDEMIOLOGY
PATHOGENESIS AND PATHOLOGY
CLINICAL MANIFESTATIONS
DIAGNOSIS
TREATMENT
PROGNOSIS
PREVENTION
219. Paracoccidioidomycosis
THE ORGANISM
TRANSMISSION
EPIDEMIOLOGY
PATHOGENESIS AND PATHOLOGY
CLINICAL MANIFESTATIONS
DIAGNOSIS
TREATMENT
PROGNOSIS
Acknowledgments
220. Cryptococcosis
ORGANISM
ECOLOGY AND EPIDEMIOLOGY
PATHOGENESIS
PULMONARY CRYPTOCOCCOSIS
CRYPTOCOCCAL MENINGOENCEPHALITIS
IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME
OTHER FORMS OF CRYPTOCOCCOSIS
TREATMENT
221. Histoplasmosis
ORGANISM
EPIDEMIOLOGY
PATHOPHYSIOLOGY
PATHOLOGY
CLINICAL MANIFESTATIONS
RADIOGRAPHIC FINDINGS
DIAGNOSIS
TREATMENT
PROGNOSIS
PREVENTION
222. Sporotrichosis
ORGANISM
EPIDEMIOLOGY
PATHOGENESIS AND PATHOLOGY
CLINICAL MANIFESTATIONS
DIAGNOSIS
TREATMENT
PROGNOSIS AND PREVENTION
223. Mucormycosis and Entomophthoramycosis
MUCORMYCOSIS
ENTOMOPHTHORAMYCOSIS
224. Fusariosis and Scedosporiosis
INFECTIONS CAUSED BY FUSARIUM SPECIES
INFECTIONS CAUSED BY SCEDOSPORIUM SPECIES
225. Miscellaneous Mycoses
YEASTS
MOLDS
Parasitic Diseases
Subsection I. Protozoa
226. Amebiasis
ETIOLOGY
EPIDEMIOLOGY
PATHOGENESIS AND PATHOLOGY
IMMUNITY
CLINICAL MANIFESTATIONS
DIAGNOSIS
COMPLICATIONS
TREATMENT
PROGNOSIS
FUTURE CONSIDERATIONS
227. Blastocystis hominis and Blastocystis spp. Infection
ETIOLOGY AND PATHOGENESIS
EPIDEMIOLOGY AND CLINICAL MANIFESTATIONS
DIAGNOSIS
TREATMENT
228. Entamoeba coli Infection
Etiology and Pathogenesis
Epidemiology and Clinical Manifestations
Diagnosis and Treatment
229. Giardiasis
Organism and Etiology
Epidemiology
Pathogenesis
Clinical Manifestations
Diagnosis
Treatment
230. Dientamoeba fragilis Infections
Organism
Epidemiology and Transmission
Clinical Manifestations
Diagnosis
Treatment
231. Trichomonas Infections
MICROBIOLOGY
PATHOLOGY AND PATHOGENESIS
EPIDEMIOLOGY
CLINICAL DIAGNOSIS AND SURVEILLANCE
TREATMENT
232. Balantidium coli Infection
Etiology and Pathogenesis
Epidemiology
Clinical Manifestations
Diagnosis
Treatment
233. Cryptosporidiosis
Microbiology
Life Cycle
Epidemiology
Transmission
Pathology and Pathogenesis
Immunology
Clinical Manifestations
Diagnosis
Management
Prevention
234. Cyclosporiasis, Cystoisosporiasis, and Microsporidiosis
CYCLOSPORA CAYETANENSIS
CYSTOISOSPORIASIS
Microbiology and Life Cycle
MICROSPORIDIOSIS
235. Babesiosis
ECOLOGY
EPIDEMIOLOGY
PATHOGENESIS AND PATHOLOGY
CLINICAL MANIFESTATIONS
DIAGNOSIS
PREVENTION AND TREATMENT
236. Malaria
HISTORY
ORGANISM
EPIDEMIOLOGY
TRANSMISSION
HOST-PARASITE INTERACTION
PATHOPHYSIOLOGY
CLINICAL MANIFESTATIONS AND LABORATORY FINDINGS
DIAGNOSIS
TREATMENT
PREVENTION
237. Leishmaniasis
ORGANISM
EPIDEMIOLOGY
OLD WORLD CUTANEOUS LEISHMANIASIS
AMERICAN CUTANEOUS LEISHMANIASIS
VISCERAL LEISHMANIASIS
COINFECTION WITH COVID-19 AND LEISHMANIASIS
238. Trypanosomiasis
AMERICAN TRYPANOSOMIASIS (CHAGAS DISEASE)
AFRICAN TRYPANOSOMIASIS (SLEEPING SICKNESS)
239. Naegleria, Acanthamoeba, and Balamuthia Infections
EPIDEMIOLOGY
ORGANISMS
CLINICAL MANIFESTATIONS
NEUROIMAGING
PATHOGENESIS
PATHOLOGY
DIAGNOSIS
TREATMENT
ROLE OF ACANTHAMOEBA SPECIES AS RESERVOIRS OF INTRACELLULAR PATHOGENS
PREVENTION
240. Toxoplasmosis
ORGANISM AND TRANSMISSION
EPIDEMIOLOGY
PATHOLOGY
IMMUNOLOGY
CLINICAL SYNDROMES
LABORATORY DIAGNOSIS
TREATMENT
PREVENTION
Acknowledgments
241. Pneumocystis Pneumonia
ORGANISM
TRANSMISSION AND EPIDEMIOLOGY
IMMUNOPATHOGENESIS
PATHOLOGY
CLINICAL MANIFESTATIONS
DIAGNOSIS
PROGNOSIS
TREATMENT
PREVENTION
Subsection II. Nematodes
242. Parasitic Nematode Infections
INTESTINAL NEMATODES
ABERRANT INFECTIONS WITH INTESTINAL NEMATODES
OTHER ABERRANT INFECTIONS WITH INTESTINAL NEMATODES
FILARIAL PARASITES
Subsection III. Cestodes
243. Cestodes
Overview of Cestodes and their Importance for Children
Taenia Saginata (Beef Tapeworm) Infection
Taenia Asiatica (Asian Pork Tapeworm)
Taenia Solium
Coenurosis (Taenia Multiceps, Others) and Cysticercosis Caused by Taenia Crassiceps
Dibothriocephalus Spp. and Adenocephalus Spp. (Fish Tapeworm)
Dipylidium Caninum (Dog Tapeworm)
Hymenolepis Nana (Dwarf Tapeworm)
Hymenolepis Diminuta (Rat Tapeworm)
Sparganosis (Intermediate-Stage Spirometra Species Infection)
Echinococcus Granulosus Sensu Lato and Related Species (Cystic Hydatid Disease)
Other Echinococcus Species
Subsection IV. Trematodes
244. Foodborne Trematodes
Liver Flukes
Lung Fluke
Intestinal Flukes
245. Schistosomiasis
INTRODUCTION
EPIDEMIOLOGY
PATHOGENESIS AND IMMUNITY
CLINICAL MANIFESTATIONS
DIAGNOSIS
TREATMENT
PREVENTION
Subsection V. Arthropods
246. Arthropods
Ticks
Mites
Lice
Bed Bugs
Spiders
Scorpions
Fleas
Section 23. Global Health
247. Global Health
DEFINITION OF GLOBAL HEALTH
HISTORY AND EVOLUTION OF GLOBAL HEALTH
SOCIAL DETERMINANTS OF HEALTH
GLOBAL GOALS FOR GLOBAL HEALTH
FUTURE DIRECTION OF GLOBAL HEALTH
248. International Travel Considerations for Children
PEDIATRIC TRAVELERS VISITING FRIENDS AND RELATIVES
PRETRAVEL CONSULTATIONS FOR CHILDREN
PEDIATRIC TRAVELERS AND HEALTH RISKS ABROAD
GENERAL APPROACH TO PRETRAVEL ASSESSMENT FOR CHILDREN
SPECIAL CONSIDERATIONS FOR MEDICAL HISTORY
THE TRAVEL ITINERARY
VACCINATION FOR INTERNATIONAL TRAVEL
PREVENTION OF TRAVELERS’ DIARRHEA IN CHILDREN
PREVENTION OF OTHER INFECTIOUS DISEASES IN PEDIATRIC TRAVELERS
EMERGENCY MEDICAL CARE DURING TRAVEL
RESOURCES FOR PEDIATRIC TRAVELERS
Acknowledgments
249. Infectious Disease Considerations in International Adoptees and Refugees
OVERALL EVALUATION
INFECTIOUS DISEASE SCREENING
OTHER VACCINE-PREVENTABLE DISEASES
IMMUNIZATION GUIDELINES
CONCLUSION
Part IV. Therapeutics
250. Antibiotic Resistance
Resistance Genetics
Resistance to Specific Antibiotics
The Intersection of Covid-19 and Antimicrobial Resistance
251. The Pharmacokinetic-Pharmacodynamic Interface: Determinants of Antiinfective Drug Action and Efficacy in Pediatrics
PHARMACOKINETIC DETERMINANTS OF EXPOSURE
BASIC TERMS
IMPACT OF ONTOGENY ON PHARMACOKINETICS
PHARMACOKINETIC DETERMINANTS OF EFFECT
PHARMACODYNAMIC DETERMINANTS OF EFFECT
PHARMACOGENETIC-PHARMACOGENOMIC DETERMINANTS OF EFFECT
MODEL INFORMED DRUG DEVELOPMENT FOR ANTIIFECTIVE USE IN PEDIATRICS
CONCLUSIONS AND IMPLICATIONS FOR PRECISION THERAPEUTICS IN INFECTIOUS DISEASE
252. Antibacterial Therapeutic Agents
CLINICAL PHARMACOLOGY
AGENTS THAT TARGET THE CELL WALL
AGENTS THAT TARGET PROTEIN SYNTHESIS
AGENTS THAT TARGET NUCLEIC ACIDS
SELECTED ASPECTS OF THE ADMINISTRATION OF ANTIMICROBIAL AGENTS
SUMMARY AND CONCLUSIONS
253. Antimicrobial Prophylaxis
GENERAL PRINCIPLES OF PROPHYLAXIS
PROPHYLAXIS IN NEONATES
DISEASE-TARGETED PROPHYLAXIS
COVID-19 INFECTION
POSTEXPOSURE PROPHYLAXIS
HOST-TARGETED PROPHYLAXIS
SURGICAL PROPHYLAXIS
254. Outpatient Intravenous Antimicrobial Therapy for Serious Infections
EVALUATING A CHILD AND PARENTS FOR OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY
THE OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY PROGRAM
Selection of an Antimicrobial Agent
Delivery of Antimicrobial Agents
OUTCOME ANALYSIS
SUMMARY
255. Antiviral Agents
Antiviral Agents Active Against RNA Viruses
Antiviral Agents Active Against DNA Viruses
256. Antifungal Agents
AGENTS FOR TREATMENT OF INVASIVE MYCOSES
Agents for Systemic Treatment of Mycoses of the Skin and Its Appendages
TOPICAL ANTIFUNGAL AGENTS
FUTURE DIRECTIONS
257. Drugs for Parasitic Infections
258. Immunomodulating Agents
MICROBIOME
VACCINATIONS AND VACCINES
MONOCLONAL ANTIBODIES
CYTOKINES
INTERFERONS
TOLL-LIKE RECEPTORS
NEUTROPHILS AND COMPLEMENT
BACTERICIDAL/PERMEABILITY-INCREASING FACTOR, DEFENSINS, AND NEUTROPHIL EXTRACELLULAR TRAPS (NETs)
PLATELET-ACTIVATING FACTOR
NITRIC OXIDE
NANOTECHONOLOGY AND OTHER NOVEL TECHNIQUES
CONCLUSION
259. Probiotics
DEFINITIONS
MECHANISM OF ACTION
PROBIOTICS AND PREBIOTICS FOR PREVENTION AND TREATMENT OF CLINICAL CONDITIONS
SAFETY OF PROBIOTICS AND PREBIOTICS IN INFANTS AND CHILDREN
INFECTIOUS DISEASES RELATED TO PROBIOTIC USE
Part V. Prevention of Infectious Diseases
260. Health Care–Associated Infections
HISTORICAL BACKGROUND
SPREAD OF COMMUNICABLE INFECTIONS IN HEALTH CARE FACILITIES
HEALTH CARE–ASSOCIATED INFECTIONS DUE TO INVASIVE DEVICES AND PROCEDURES
HEALTH CARE–ASSOCIATED INFECTIONS CAUSED BY SPECIAL PATHOGENS
HEALTH CARE–ASSOCIATED INFECTIONS IN SPECIAL POPULATIONS
HEALTH CARE EPIDEMIOLOGY AND INFECTION PREVENTION AND CONTROL PROGRAMS IN HEALTH CARE FACILITIES
261. Antimicrobial Stewardship
CONSEQUENCES OF ANTIBIOTIC USE
ANTIMICROBIAL PRESCRIBING
POLICY IMPLICATIONS
INPATIENT ANTIMICROBIAL STEWARDSHIP
OUTPATIENT ANTIMICROBIAL STEWARDSHIP
ADDITIONAL HEALTH CARE SETTINGS
ADDITIONAL CONSIDERATIONS
262. Active Immunizing Agents
ACTIVE IMMUNOPROPHYLAXIS: CONSIDERATIONS AND RECOMMENDATIONS
VACCINES RECOMMENDED FOR ROUTINE ADMINISTRATION
VACCINES WITH SELECTIVE INDICATIONS FOR CHILDREN AND ADOLESCENTS
263. Passive Immunization
PRINCIPLES OF PASSIVE IMMUNITY
PASSIVE IMMUNITY IN BACTERIAL DISEASES
PASSIVE IMMUNITY IN VIRAL INFECTIONS
SARS-CoV-2
Acknowledgments
Section 24. Other Preventive Considerations
264. Public Health Aspects of Infectious Disease Control
PUBLIC HEALTH AND INFECTIOUS DISEASE CLINICIANS
PUBLIC HEALTH
INFECTIOUS DISEASE SURVEILLANCE
HOW PUBLIC HEALTH CAN ASSIST CLINICIANS
OUTBREAK INVESTIGATION
PUBLIC HEALTH PREVENTION AND CONTROL MEASURES
COMMON PATTERNS OF DISEASE SPREAD
EXAMPLES OF EXPOSURE SOURCES
VECTOR-BORNE DISEASE
COMMON DISEASE TRANSMISSION SETTINGS
HEALTH INFORMATION FOR INTERNATIONAL TRAVEL
SUMMARY
265. Infections in Out-of-Home Childcare
FACTORS AFFECTING TRANSMISSION OF INFECTIOUS AGENTS
MODES OF TRANSMISSION OF INFECTIOUS DISEASES IN OUT-OF-HOME CHILDCARE
PREVENTION AND CONTROL OF INFECTIONS IN OUT-OF-HOME CHILDCARE
INFECTIOUS AGENTS IN CHILDCARE
266. Animal and Human Bites
HISTORICAL ASPECTS
EPIDEMIOLOGY
MICROBIOLOGY
CLINICAL MANIFESTATIONS
DIAGNOSIS AND TREATMENT
REPTILE BITES
PREVENTION
267. Bioterrorism
HISTORY
EPIDEMIOLOGY
PREPAREDNESS AND RESPONSE
CRITICAL BIOLOGIC AGENTS
Part VI. Approach to the Laboratory Diagnosis of Infectious Diseases
268. Bacterial Laboratory Diagnosis
CULTURE-BASED DETECTION
Antimicrobial Susceptibility Testing
NON–CULTURE-BASED DETECTION METHODS
269. Fungal Diagnostics for Pediatric Patients
PREANALYTICAL CONSIDERATIONS
CULTURE-DEPENDENT METHODS FOR THE DETECTION OF IFDs
CULTURE-INDEPENDENT METHODS FOR THE DETECTION OF IFDs
ANTIFUNGAL SUSCEPTIBILITY TESTING
POSTANALYTICAL CONSIDERATIONS
270. Viral Laboratory Diagnosis
Specimen Collection and Transport
Laboratory Diagnosis of Viral Infections
SARS-CoV-2 Diagnostics
Summary
Acknowledgment
271. Parasitic Laboratory Diagnosis
STOOL-BASED DETECTION
Processing of Stool Samples
Other Tissue or Body Fluids for Parasite Detection
Blood Parasites
Molecular Testing
Index
（紀伊國屋書店 学術洋書部）
